Business
Majority of Stockholders Support Pasithea Directors at Special Meeting
MIAMI BEACH, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused
About this update from Pasithea Therapeutics Corp.
[{"type":"text","content":"MIAMI BEACH, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders, today announced the final results of the Special Meeting of Stockholders (“Special Meeting”) held on December 9, 2022. According to the certified voting results provided by the Independent Inspector of Elections, a significant majority of Pasithea stockholders rejected all of the proposals asserted by a dissident group of stockholders. Of the votes cast at the Special Meeting, approximately 67% rejected the proposals to remove the Company’s directors, representing approximately 12.7 million shares or approximately 44% of the total outstanding shares. As a result, the current members of the Company’s Board will continue to serve and oversee Pasithea’s business strategy. The final certified results will be filed on a Form 8-K with the Securities and Exchange Commission. Dr. Tiago Reis Marques, Pasithea’s Chief Executive Officer, stated, “We thank our stockholders for their support at the Special Meeting and look forward to continue working diligently to develop our product pipeline in an effort to provide groundbreaking therapies for patients and drive value creation for all Pasithea stockholders.” About Pasithea Therapeutics Corp. Pasithea Therapeutics is a biotechnology company primarily focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis, Neurofibromatosis type 1 and Noonan syndrome. Forward Looking Statements This press release contains statements that constitute “forward-looking statements.” Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this rel...